The Neurofibromatosis Treatment Drugs marketplace is forecasted to expand at a faster rate in the forthcoming years and is predicted to rise at a considerable compound yearly growth rate (CAGR), thus proving to be a highly profitable industry for pharmaceuticals manufacturers. These drugs are specifically designed to counter the neurophysiologic changes that can lead to the progression of the disease. Due to the fact that this disease is largely associated with heredity factors, several effective drugs have already been developed by the pharmaceutical industry to treat people who suffer from this condition. However, with the advent of new technologies, more promising drugs are in the pipeline that are expected to provide a better avenue for combating the symptoms of Neurofibromatosis. Some of these promising drugs are being tested in clinical trials presently.
While most Neurofibromatosis treatment drugs are being developed based on their activity on the primary mechanisms of action of the molecule concerned in the process of neurotransmission, several studies are currently underway to investigate the insights of Neurofibromatosis in other segments of the biological system. For instance, it has recently been found out that several naturally occurring compounds that act on the cholinergic neurons and synapses in the brain can also reverse the progress of this disorder. Most of these substances belong to the class of ergosterol esters, which have the capacity to alter the intracellular and extracellular dynamics by interacting with several cell-permeable molecules such as neurotransmitters, lipids, and receptors.
Read More : https://bit.ly/3xvBue6
